Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) held its Annual General Meeting (AGM) on August 8, 2025, with 37.42% of outstanding shares represented. The company successfully elected eight directors to its board, with approval rates ranging from 80.45% to 91.64%. The highest approval was received by Jared Kelly (91.64%), while Jonathan Rigby received the lowest support (80.45%).

Shareholders also approved additional resolutions, including fixing the board size at eight members and appointing auditors. The meeting results demonstrate strong shareholder support for the company's governance structure.

News Market Reaction

-0.84%

1 alert

-0.84% News Effect

-$679K Valuation Impact

$80M Market Cap

0.1x Rel. Volume

On the day this news was published, ONCY declined 0.84%, reflecting a mild negative market reaction. This price movement removed approximately $679K from the company's valuation, bringing the market cap to $80M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:

Director	For	%	Withheld	%
Patricia Andrews	10,498,328	88.83 %	1,320,714	11.17 %
Deborah M. Brown	10,115,110	85.58 %	1,703,932	14.42 %
Jared Kelly	10,830,605	91.64 %	988,437	8.36 %
Angela Holtham	10,175,887	86.10 %	1,643,155	13.90 %
James T. Parsons	10,172,958	86.07 %	1,646,084	13.93 %
Wayne Pisano	10,148,894	85.87 %	1,670,148	14.13 %
Jonathan Rigby	9,508,770	80.45 %	2,310,272	19.55 %
Bernd R. Seizinger	10,269,441	86.89 %	1,549,601	13.11 %

In addition to the election of all nominees listed as directors in the management information circular, dated June 18, 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.

For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at https://www.sedarplus.ca/home/. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.

Company Contact

Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca 

Investor Relations for Oncolytics

Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com 

Media Contact for Oncolytics

Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com 

Logo - https://mma.prnewswire.com/media/2408622/5454862/Oncolytics_Biotech_Inc_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-302526856.html

SOURCE Oncolytics Biotech® Inc.

FAQ

What was the shareholder participation rate at Oncolytics Biotech's (ONCY) 2025 AGM?

The AGM had 37.42% of the company's issued and outstanding common shares represented either in person or by proxy.

Who received the highest approval rating among ONCY's director nominees in 2025?

Jared Kelly received the highest approval rating with 91.64% of votes in favor.

How many directors were elected to Oncolytics Biotech's board in 2025?

Eight directors were elected to serve until the next Annual Meeting of Shareholders or until their successors are elected or appointed.

What was the lowest approval rating received by an ONCY director nominee in 2025?

Jonathan Rigby received the lowest approval rating with 80.45% of votes in favor.